Primary IgA nephropathy : FDA grants full approval to Travere Therapeutics’ Filspari
In a groundbreaking move, the US Food and Drug Administration (FDA) has granted full approval to Travere Therapeutics' Filspari (sparsentan) for treating primary IgA nephropathy ... Read More
FDA grants Otsuka’s Sibeprenlimab breakthrough therapy designation in IgAN
In a significant development for the treatment of kidney disease, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sibeprenlimab, an ... Read More